Medical Device Approval Process by Risk Classification – pharmacovigilance Medical Device Approval Process by Risk Classification in Uzbekistan (MOH) Step 1: Understanding the Regulatory Framework for Medical Devices in Uzbekistan Before embarking on the medical device approval process in Uzbekistan, it is imperative to have a comprehensive understanding of the existing regulatory framework. The Ministry of Health (MOH) oversees the regulation of medical devices within the country, and this framework is established to ensure safety, efficacy, and quality. The foundation of this regulatory oversight is rooted in the Law on the Protection of Citizens’ Health, which lays out the basic…

Role of Local Agents and Technical Partners in Registration – pharmacovigilance Role of Local Agents and Technical Partners in Registration – pharmacovigilance The successful registration of pharmaceutical products in Malawi, as governed by the Pharmacy and Medicines Regulatory Authority (PMRA), necessitates a comprehensive understanding of the regulatory landscape. This guide elucidates the role of local agents and technical partners in pharmacovigilance, focusing on their importance during the registration process. Professionals engaged in regulatory affairs, quality assurance (QA), pharmacovigilance (PV), and chemistry, manufacturing, and controls (CMC) will benefit from a structured, step-by-step approach outlined herein. Step 1: Understanding the Regulatory Framework…

Clinical Trial Regulations and Ethics Approval Requirements – pharmacovigilance Clinical Trial Regulations and Ethics Approval Requirements in the Dominican Republic The clinical trial landscape in the Dominican Republic is governed by the Ministry of Public Health, particularly through the Directorate General of Medicines, Food and Health Products (DIGEMAPS). This detailed guide will provide a step-by-step approach to understanding and implementing the regulations, specifically focusing on pharmacovigilance, a critical component of drug safety monitoring during and after clinical trials. By following this tutorial, regulatory affairs professionals will be equipped with the knowledge to navigate these essential regulations effectively. Step 1: Understanding…

Market Surveillance, Quality Monitoring, and Enforcement – pharmacovigilance Market Surveillance, Quality Monitoring, and Enforcement – pharmacovigilance Step 1: Understanding Pharmacovigilance and Regulatory Framework in Kenya Pharmacovigilance (PV) is an essential component of maintaining drug safety and efficacy post-marketing. In Kenya, pharmacovigilance falls under the jurisdiction of the Pharmacy and Poisons Board (PPB), which ensures that all pharmaceutical products on the market are monitored for safety. The regulatory landscape is shaped by the national guidelines that align with international standards such as those set by the World Health Organization (WHO). The primary aim of pharmacovigilance is to detect, assess, understand, and…

Regulatory Pathway for Biosimilars and Biologics in Ukraine – pharmacovigilance Regulatory Pathway for Biosimilars and Biologics in Ukraine This article serves as a comprehensive tutorial guide aimed at regulatory affairs professionals, quality assurance teams, and pharmacovigilance (PV) specialists looking to navigate the regulatory landscape for biosimilars and biologics in Ukraine. In an evolving global market, understanding the pharmacovigilance requirements and processes outlined by the State Medical Device Control Agency (SMDC) under the Ministry of Health of Ukraine is essential for compliant drug development and marketing. The following sections detail each step of the regulatory pathway, focusing on preparation, submission, review,…

Risk Mitigation Strategies During Early Phase IND Trials – pharmacovigilance Risk Mitigation Strategies During Early Phase IND Trials Early-phase clinical trials are critical in the drug development process, as they serve to establish the safety, tolerability, and pharmacokinetics of investigational products. Pharmacovigilance signifies the science and activities concerning the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. This article provides a thorough tutorial on implementing effective risk mitigation strategies during early-phase Investigational New Drug (IND) trials, focusing on pharmacovigilance methodologies consistent with FDA, EMA, and ICH guidelines. Step 1: Understand Regulatory Framework and Requirements Before…

Regulatory Pathways for Nutraceuticals and AYUSH Products – pharmacovigilance Regulatory Pathways for Nutraceuticals and AYUSH Products – pharmacovigilance Step 1: Understanding the Regulatory Framework for Nutraceuticals and AYUSH Products The regulatory landscape for nutraceuticals and AYUSH products in India is multifaceted and involves several agencies, primarily the Central Drugs Standard Control Organization (CDSCO). Understanding this framework is essential for regulatory affairs professionals. As a starting point, it is crucial to recognize that nutraceuticals, often viewed as products derived from food sources, are not classified as drugs under the Drugs and Cosmetics Act, 1940. AYUSH products, which include Ayurvedic, Yoga, Naturopathy,…

Risk Management in NDAs and BLAs: Benefit–Risk Strategy and Label Impact Designing Benefit–Risk for NDAs/BLAs: Strategy, Evidence, and the Label You’ll Live With Why Benefit–Risk Drives Approval and the Label: A Practical Orientation for CMC, Clinical, and RA Teams Every New Drug Application (NDA) or Biologics License Application (BLA) lives or dies on a coherent benefit–risk argument. Put simply, regulators must be convinced that, for the intended population, the benefits under proposed use outweigh foreseeable risks, and that any residual risks are effectively minimized and monitored over the product lifecycle. That decision is not a single meeting—it is a thread…

Labeling Variations Made Practical: Safety Updates, Formatting Changes, and SPL Requirements Operational Guide to Labeling Variations: Managing Safety Updates, Formatting Edits, and SPL Submissions Why Labeling Variations Matter: Patient Safety, Compliance Risk, and Business Continuity Product labeling is the living expression of a medicinal product’s benefit–risk profile. Whether you manage a U.S. Prescribing Information (USPI), Medication Guide, EU Summary of Product Characteristics (SmPC), or Patient Information Leaflet (PIL), labeling variations ensure new safety information is communicated accurately and on time. Missed or mishandled updates can lead to inspection findings, health authority (HA) queries, stock rework, or worse—patient harm. For companies…